Signet Healthcare Partners Closes Fourth Private Equity Life Sciences Fund, at $137.2M

signetSignet Healthcare Partners, a New York-based private equity firm that provides growth capital to commercial Life Sciences companies, closed its latest fund at $137.2m.

Signet Healthcare Partners IV, L.P., will typically invest $10-15 million per company (with co-investment from its limited partners) in 10-12 companies that are revenue generating or preparing for commercial launch.

Led by James Gale, Founding Partner and Managing Director, and new general partners Nikhil Puri and Ashley Friedman, the firm primarily focuses on the pharmaceutical sector and medical technology companies.
Signet has raised four funds with total capital commitments of over $400m investing in more than 45 companies.

Nikhil Puri has joined Signet from Pfizer, where he was Vice President and Head of Business Development for the Global Established Pharmaceuticals business. Prior to that, Mr. Puri had spent 15 years as an investment banker, most notably at Bear Stearns and Lehman Brothers.
Ashley Friedman had previously been a venture partner since 2014 when he joined Signet from Investor Growth Capital (the private equity and venture arm of Investor AB). While at Investor, Mr. Friedman participated in and led a number of life science private equity financings. He started his career at Lehman Brothers.



Join the discussion